Sintropium Bromide

We present a case of an 80-year-old male who was referred to the Department of Oral Medicine, School of Dental Medicine University of Zagreb, Croatia due to gingival ulcer which was present for eight days. Clinical examination has revealed exposed bone on the toothless alveolar ridge in the lower molar region on the right side of 0.8 cm in diameter. Otherwise, the patient was taking doxazosin due to urinary problems and ipatropium bromide due to respiratory problems. The patient wore a 6-year-old partial lower denture. He was initially treated with periodontal bandage (Resopack, HagenWerken, Germany) for the first three days and was instructed not to wear the denture; however, no benefit could be seen. Therefore, we added a local corticosteroid (betamethasone) and am oral antiseptic (chlorhexidine digluconate) applied three times a day. After 3 weeks the lesion healed. A list of possible causative factors regarding gingival ulcers is included.

Anti-cholinergics have been considered the first-choice bronchodilator therapy in the routine management of stable COPD. Muscarinic cholinergic receptors are expressed on most cell types and mediate cellular signalling via the natural ligand, acetylcholine. Antagonising cholinergic receptors may not only result in bronchodilation, but also have associated localised activity. Until recently the licensed anti-cholinergics were limited to ipatropium bromide, oxitropium bromide and tiotropium bromide; the latter being the only once-daily anti-cholinergic. With the patents expired or due to expire shortly several companies have reinitiated efforts to develop safer, long-acting agents potentially improving concordance and pharmaceutical marketing opportunities. The present article reviews a number of novel anti-cholinergics that have been recently licensed and those undergoing development, some in innovative delivery devices.